Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02237157 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer
A Phase 1 study, sponsored by RenovoRx.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02237157 is a Phase 1 study that has completed, run by RenovoRx. The registered enrollment target is 20 participants.
The verdict
NCT02237157, a Phase 1 study, has completed, sponsored by RenovoRx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
Interventions
- DRUG Gemcitabine, local delivery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02237157
The ClinicalTrials.gov registry entry for NCT02237157 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RenovoRx, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gemcitabine, local delivery is the first listed.
NCT02237157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02237157 about?
NCT02237157 is a clinical study titled "A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer". A dose escalation, safety study of local (intra-arterially) delivered gemcitabine to the pancreas using the RenovoCath R120 catheter to determine the maximum tolerated dose.
What is the current status of trial NCT02237157?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02237157?
The interventions under investigation include: Gemcitabine, local delivery (DRUG).
Who is sponsoring clinical trial NCT02237157?
This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.